NEW YORK (GenomeWeb News) – Rosetta Genomics said today it has struck an agreement with the University of California, Irvine, School of Medicine to work together to validate diagnostic tests based on the company’s microRNA technology.
Under the agreement, the CLIA-certified medical school and the company will work together to validate tests that are designed to differentiate squamous from non-squamous lung cancer and to differentiate mesothelioma from adenocarcinoma, as well as to identify cancers of unknown primary origin.
Rosetta Genomics, which is based in Rehovot, Israel, and has operations in Jersey City, NJ, also said it expects to launch three microRNA diagnostic tests in clinical laboratories sometime this year.
Financial terms of the agreement were not released.